Protembis

Series-B+
protembis.com Biotech & Healthcare
Total Funding $42.5M
Latest Round $32.5M Series-B+
Last Announced Mar 26, 2024
Investors Undisclosed
Decision Makers 5 Verified

About Protembis

Mitigating large brain lesions during TAVR. TAVR procedures can cause large brain infarcts, which may lead to procedural clinical stroke and an increased risk of future stroke, cognitive decline, and dementia.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B+
Global Headquarters Undisclosed
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website protembis.com
Domain Registered Date Oct 3, 2013

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

3 Events
  1. Capital Raise

    Raised $32,500,000 · Series-B+

    startupintros.com

  2. Capital Raise

    Raised $10,000,000 · Series-A

    startupintros.com

  3. Milestone

    Website domain registered

    protembis.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Protembis.

Funding History

2 Rounds
Series-B+ · Mar 26, 2024
Series-A · Oct 26, 2018

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts